Essure Permanent Birth Control Class Action
Merchant Law Group LLP is prosecuting against the manufacturers of Essure Permeant Birth Control Device (“Essure”), class action litigation seeking individual compensation and other benefits for Canadian women who have been implanted with Essure and have experienced certain physical injuries or complications.
The Essure Canada Class Actions seek proper financial compensation for affected Canadian women who have suffered as a result of using the Essure implant. Please note, joining our contact list for the Essure Class Action creates no financial obligation for you and your information will be kept confidential.
If you have had Essure implants (with or without complications), please contact one of our personal injury lawyers with any questions, by emailing essureinfo@merchantlaw.com
The manufacturers of Essure are Bayer Inc., Bayer AG, Bayer Corporation, and Bayer Health Care LLC.
IF YOU WISH TO JOIN THE CONTACT LIST FOR THIS CLASS ACTION OR TO SIMPLY GET MORE INFORMATION, PLEASE COMPLETE THE BELOW FORM [OR EMAIL OUR LAW FIRM AT essureinfo@merchantlaw.com].
Background of this Personal Injury Litigation
While the ESSURE implant was marketed as a safe and permanent form of birth control, the lawsuits allege that ESSURE increased the risk of severe chronic pain, discomfort, bleeding, pain during sex, cramping, swelling, bloating, irregular menstrual cycles, migration of the implants, and on balance, was unfit for its intended use. It is alleged that Bayer failed to conduct adequate pre- and post-market testing, and of greatest concern, to adequately warn the Class of the significant risk of adverse effects, or to promptly remove Essure from the market, as these significant adverse risks became known. For example, in 2016, after becoming aware of a new research study that raised safety concerns about ESSURE, Health Canada conducted its own safety review and “recommended increased monitoring of the safety of the Essure” while also requiring that “the manufacturer to issue a risk communication to help clarify information about the device and associated safety concerns.” However, these were not newly discovered issues. As the United States Food and Drug Administration reports, adverse event reports were being received as early as 2002:From 2002 through 2021, the most reported patient problems were pain/abdominal pain (38,995), heavier menses/hemorrhage/menstrual irregularities (17,542), foreign body/device fragment in patient (10,151), perforation (9,295), headache (8,705), fatigue (7,206), weight fluctuations (6,087), depression/anxiety (5,749), hypersensitivity/rash (5,368), and hair loss (5,099). Most of the reports received listed multiple patient problems in each report. The most frequent device problems reported were patient-device incompatibility/biocompatibility (for example, possible nickel allergy or patient’s anatomy related to failure) (8,625), migration of the device or device component (5,598), device breakage/material fragmentation/fracture (2,935), dislodged or dislocated device (2,814), device operating differently than expected, for example, implant failure or pregnancy (1,137), malposition of the device (415), device difficult to remove (348), and device difficult to insert (339). Multiple device problems can also be listed in each report.In 2017, Bayer announced that it would voluntarily withdraw ESSURE from the Canadian market. On December 31, 2018, Bayer stopped selling the ESSURE birth control product in the United States, although the FDA has mandated extensive follow-up studies to monitor those who already have ESSURE implants.